<DOC>
	<DOCNO>NCT01201265</DOCNO>
	<brief_summary>This multicenter study assess efficacy safety bevacizumab combination gemcitabine cisplatin first line treatment participant triple negative metastatic breast cancer . Participants receive bevacizumab dose 15 mg/kg intravenously ( iv ) every 3 week , plus gemcitabine ( 1000 mg/m2 iv ) carboplatin ( iv area curve [ AUC ] =2 ) Days 1 8 3-week cycle . Anticipated time study treatment disease progression .</brief_summary>
	<brief_title>A Study Bevacizumab Combination With Gemcitabine Carboplatin Participants With Triple Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Female participant , &gt; /= 18 year age Metastatic breast cancer Estrogen receptor , progesterone human epidermal growth factor receptor 2 ( HER2 ) negative disease Treatmentna√Øve metastatic breast cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Adequate hematological , renal liver function Patients receive Anthracyclines Taxanes adjuvant set Women childbearing potential must agree use adequate contraception ( per institutional standard care ) treatment 6 month last administration investigational product Prior first line treatment metastatic breast cancer Central nervous system ( CNS ) metastasis Uncontrolled hypertension ( &gt; 170/95 mmHg ) Evidence bleed diathesis , coagulopathy hemorrhage baseline Other malignancy within last 5 year , except adequately treat carcinoma situ cervix squamous carcinoma skin , adequately control limited basal cell skin cancer . Prior therapy gemcitabine carboplatin metastatic setting . Participants receive gemcitabine carboplatin part adjuvant therapy eligible , recurrence first document &gt; 6 month last exposure drug ( ) Requirement chronic use immunosuppressive agent HIV , hepatitis B hepatitis C infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>